CV-4151--a potent, selective thromboxane A2 synthetase inhibitor

Area of Science:

• Biochemistry
• Pharmacology
• Cardiovascular Research

Background:

• Thromboxane A2 (TXA2) plays a critical role in platelet aggregation and vasoconstriction.
• Inhibiting TXA2 synthetase is a therapeutic strategy to modulate prothrombotic and vasoconstrictive processes.
• Selective inhibition of TXA2 synthetase without affecting other cyclooxygenase or lipoxygenase pathways is desirable.

Purpose of the Study:

• To evaluate the inhibitory potential and selectivity of (E)-7-Phenyl-7-(3-pyridyl)-6-heptenoic acid (CV-4151) on thromboxane A2 (TXA2) synthetase.
• To compare the efficacy and duration of action of CV-4151 with other known TXA2 synthetase inhibitors.
• To investigate the in vivo effects of CV-4151 on TXA2 production and prostaglandin metabolism.

Main Methods:

• In vitro enzymatic assays to determine the IC50 values against TXA2 synthetase, cyclooxygenase, PGI2 synthetase, and 5-lipoxygenase.
• In vitro and ex vivo experiments assessing PGI2 release from aortic tissues.
• In vivo studies in rats and dogs involving oral and intravenous administration of CV-4151 to measure TXA2 synthetase activity, serum TXB2, and 6-keto-PGF1α levels.
• Comparison with reference compounds like aspirin, OKY-1580, and dazoxiben.

Main Results:

• CV-4151 demonstrated potent and selective inhibition of horse platelet microsomal TXA2 synthetase (IC50 = 2.6 x 10(-8) M) with minimal impact on other enzymes.
• It did not affect PGI2 release in vitro or ex vivo, unlike aspirin.
• In rats and dogs, oral CV-4151 markedly inhibited blood TXA2 synthetase activity (ID50 = 0.05 mg/kg in rats, 0.17 mg/kg in dogs) with prolonged effects lasting over 24 hours.
• CV-4151 increased serum 6-keto-PGF1α and decreased serum TXB2, indicating a shift in prostaglandin metabolism.
• It was more potent and longer-acting in vivo than OKY-1580.

Conclusions:

• CV-4151 is a potent, selective, and long-acting inhibitor of TXA2 synthetase.
• Its administration leads to reduced TXA2 production and potentially favors PGI2 formation.
• CV-4151 shows promise as a therapeutic agent for conditions involving excessive TXA2 activity.